Cefoxitin
Type of Medication: Antibiotic
Indications: Treatment of Mycobacterium abscessus infections
Side Effects: Thrombophlebitis, maculopapular exanthema, erythema, TEN, urticaria, flushing, pruritis, oedema, fever, allergic reaction including anaphylaxis, interstitial nephritis. GI disorders including nausea , vomiting, diarrhoea, abdominal pain and pseudomembranous colitis. Eosinophilia, leukopenia, neutropenia, thrombocytopenia, anaemia and bone marrow depression have been reported. Increases in serum levels of urea and creatinine and on occasions acute renal failure have been reported. Transient increases in AST, ALT and alkaline phosphotase have also been reported.
Route of administration: Adult (Intravenous)
Dose: 3 g qds (200 mg/kg/day in three divided doses – maximum 12 g/ day)
Administration: Give in 100 mls of sodium chloride 0.9% or dextrose 5 % over 60 minutes.
Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations
Route of administration: Paediatric (Intravenous)
Dose: 200 mg/kg per day in 3 to 4 divided doses. Children aged 1 month and above. 150 mg/kg/day in 3–4 divided doses (maximum 12 g/day)
Administration: Give in 100 mls of sodium chloride 0.9% or dextrose 5 % over 60 minutes
Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations
Examples of some Drug Interactions
Interacting drug: aminoglycosides: increased risk of nephrotoxicity
Interacting drug: anticoagulants: increased INR with warfarin/pirfenidone
Interacting drug: furosemide: increased risk of nephrotoxicity
Interacting drug: probenecid: reduced renal excretion of cefoxitin, resulting in increased and prolonged serum levels.
Interacting drug: Typhoid vaccine: Drecreased immunological response to vaccine